Hathal Haddad, Head of Interventional Radiotherapy Unit at University Hospital Tübingen, shared a post on LinkedIn:
“14 Days Until Brachytherapy Awareness Day 2026. Focal Interventional Radiotherapy (Brachytherapy).
A New Era of Focal and Organ-Preserving Salvage Treatment for Prostate Cancer.
Local recurrence after radiotherapy does not always mean the end of curative treatment.
For carefully selected patients, focal salvage HDR brachytherapy offers a second chance for cure while treating only the recurrent tumor and preserving the remainder of the prostate and surrounding organs.
A recently published prospective study demonstrated encouraging long-term outcomes with excellent safety using MRI- and PSMA PET-guided focal HDR brachytherapy delivered in two fractions of 13.5 Gy.
Key Results
- 59 patients
- Median follow-up: 54 months
- 3-year biochemical failure-free survival: 54%
- Freedom from ADT or repeat salvage therapy: 82%
- Late Grade ≥3 GU toxicity: 1.7%
- Late Grade ≥3 GI toxicity: 0%
Why focal salvage HDR brachytherapy?
- Treats only the recurrent lesion.
- Preserves uninvolved prostate tissue.
- MRI- and PSMA PET-guided precision.
- Minimally invasive outpatient procedure.
- Preserves urinary and bowel function.
- Organ-preserving alternative for carefully selected patients.
This study highlights the evolution of Interventional Radiotherapy (Brachytherapy) toward increasingly personalized, image-guided, and less invasive cancer care.
Treat less. Preserve more. Cure when possible.
Brachytherapy saves lives.
17 July 2026 – Brachytherapy Awareness Day.”
Other articles about Brachytherapy on OncoDaily.